Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Publication | Closed Access

DOI

160

Citations

References

2019

Year

David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei,

The Lancet HIV

Week 96Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirologyPharmacotherapyNon-inferiority TrialHiv-1 InfectionAntiviral DrugHivMedicineViral Immunity